A series of trials of CAR‐T cells treatment have shown that MUC1, HER‐2, EGFR, CD70, LMP1, CD44v6, CD276 (B7‐H3), CD98hc, NKG2DL, FAP, HER3, and NKGD2 are promising CAR‐targeted proteins for HNSCC immunotherapy180 (Figure 5B). This evidence concerns the gene ERBB3 and head and neck squamous cell carcinoma.